paroxetine has been researched along with lamotrigine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 11 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Labbate, LA; Rubey, RN | 1 |
| Calabrese, JR; Kimmel, SE; Rapport, DJ; Shelton, MD | 1 |
| Grunze, H; Hörn, M; Hummel, B; Normann, C; Schärer, LO; Walden, J | 1 |
| Berger, M; Fiebich, BL; Grunze, H; Lieb, K; Normann, C; Walden, J | 1 |
| Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J | 1 |
| Jakovljevic, M; Kramaric, M; Muck-Seler, D; Mustapic, M; Nedic, G; Peles, AM; Pivac, N; Sagud, M | 1 |
| Blom, MB; Hartong, EG; Mulder, P; Nolen, WA; Timmermans, MA; van der Loos, ML; van Noorden, MS; Vergouwen, AC; Vieta, E | 2 |
| LeBlanc, SR; Ovanessian, MM; Parikh, SV | 1 |
| Barbee, JG; Conrad, EJ; Jamhour, NJ; Reimherr, FW; Shelton, RC; Stewart, JW; Thompson, PM; Thompson, TR | 1 |
| Bettica, P; Danhof, M; Della Pasqua, O; Gomeni, RA; Santen, G; van Zwet, E | 1 |
| Asz-Sigall, D; Guzmán-Sánchez, D | 1 |
3 review(s) available for paroxetine and lamotrigine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Controlled trials in bipolar I depression: focus on switch rates and efficacy.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Antimanic Agents; Bipolar Disorder; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Lamotrigine; Moclobemide; Paroxetine; Triazines | 1999 |
Alopecias due to drugs and other skin and systemic disorders.
Topics: Alopecia; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Dermatologic Agents; Dermatomycoses; Diet; Folliculitis; Herpes Zoster; HIV Infections; Humans; Isotretinoin; Lamotrigine; Lithium Compounds; Lupus Erythematosus, Systemic; Malnutrition; Mycosis Fungoides; Paroxetine; Sarcoidosis; Seasons; Skin Neoplasms; Starvation; Stress, Psychological; Syphilis; Triazines; Valproic Acid | 2015 |
6 trial(s) available for paroxetine and lamotrigine
| Article | Year |
|---|---|
Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lamotrigine; Male; Middle Aged; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Triazines | 2002 |
Serum levels of substance P and response to antidepressant pharmacotherapy.
Topics: Acute Disease; Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Lamotrigine; Paroxetine; Severity of Illness Index; Substance P; Surveys and Questionnaires; Triazines | 2004 |
Motor cortex excitability after vagus nerve stimulation in major depression.
Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid | 2007 |
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine.
Topics: Adult; Algorithms; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Middle Aged; Netherlands; Paroxetine; Psychiatric Status Rating Scales; Psychometrics; Triazines | 2010 |
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium Compounds; Male; Middle Aged; Paroxetine; Treatment Outcome; Triazines; Young Adult | 2011 |
A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lamotrigine; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Triazines | 2011 |
13 other study(ies) available for paroxetine and lamotrigine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Lamotrigine for treatment-refractory bipolar disorder.
Topics: Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Humans; Lamotrigine; Male; Middle Aged; Paroxetine; Thyroxine; Triazines | 1997 |
The effect of lamotrigine on platelet serotonin concentration in patients with bipolar depression.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Blood Platelets; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Lamotrigine; Lithium Compounds; Middle Aged; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Serotonin; Triazines | 2008 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Bupropion; Combined Modality Therapy; Comorbidity; Database Management Systems; Humans; Inositol; Lamotrigine; Multicenter Studies as Topic; Paroxetine; Psychotherapy, Brief; Randomized Controlled Trials as Topic; Recurrence; Research Design; Risperidone; Smoking; Substance-Related Disorders; Suicide; Treatment Outcome; Triazines; United States; Vitamin B Complex | 2010 |
From trial and error to trial simulation III: a framework for interim analysis in efficacy trials with antidepressant drugs.
Topics: Antidepressive Agents; Bayes Theorem; Clinical Trials as Topic; Computer Simulation; Dose-Response Relationship, Drug; Humans; Lamotrigine; Paroxetine; Time Factors; Triazines | 2011 |